GlassScriptPhysician profile
Ameer Shams
NPI 1639369960
$3,089.95
in general payments reported to CMS, 2019-2025
32 companies · $47.76 in 2025
The $47.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2021: $354 · 2022: $1,118 · 2023: $997 · 2024: $341 · 2025: $47.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.27 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $339.24 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $261.08 | 2019-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.00 | 2019-2024 | Jardiance |
| Pfizer INC. | $212.96 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $208.58 | 2019-2024 | Belsomra, Verquvo, Gardasil 9 |
| Lilly USA, LLC | $198.84 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $177.92 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $136.04 | 2022 | |
| Glaxosmithkline, LLC. | $103.10 | 2021-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.91 | 2022-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $83.73 | 2022-2023 | Breztri |
| Amarin Pharma, INC. | $61.83 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $59.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.35 | 2019-2024 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.05 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $45.24 | 2023 | |
| Sanofi Pasteur INC. | $41.96 | 2021-2023 | |
| Saluda Medical Americas, INC. | $38.01 | 2023 | Evoke Scs |
| Astellas Pharma US INC | $36.71 | 2021 | |
| Eisai INC. | $35.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.64 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $32.49 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $26.15 | 2024 | Rexulti |
| Grifols USA, LLC | $20.57 | 2019 | |
| Clarus Therapeutics INC. | $19.44 | 2021 | |
| Corium, LLC | $18.21 | 2023 | Adlarity |
| Exact Sciences Corporation | $15.53 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $15.27 | 2025 | Qelbree |
| Mylan Specialty L.P. | $13.49 | 2023 | Yupelri |
| Ironwood Pharmaceuticals, INC | $11.74 | 2022 | |
| Dynavax Technologies Corporation | $11.44 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ameer Shams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.